URGN Q4 2017 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$918M

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$327,000-98.1% YoY

Gross Profit

$40,00012.2% margin

Operating Income

-$10M-3106.4% margin

Net Income

-$10M-3078.6% margin

EPS (Diluted)

$-0.74

QoQ Revenue Growth

-95.8%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$76M

Total Liabilities

$7M

Stockholders' Equity

$69M

Cash & Equivalents

$37M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$327,000	$18M	-98.1%
Gross Profit	$40,000	$18M	-99.8%
Operating Income	-$10M	$14M	-173.1%
Net Income	-$10M	$12M	-181.8%